Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RYTM

Rhythm Pharmaceuticals Inc

Sep 12 • 04:00PM ET

96.22

-1.70 -1.74 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE VRTX MRK NVO SNY LLY TAK VTRS XENE NBIX

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.02	Insider Own	7.54%	Shs Outstand	63.91M	Perf Week	-5.78%
Market Cap	6.39B	Forward P/E	-	EPS next Y	-2.01	Insider Trans	-7.33%	Shs Float	61.41M	Perf Month	-1.68%
Enterprise Value	6.36B	PEG	-	EPS next Q	-0.71	Inst Own	95.10%	Short Float	8.09%	Perf Quarter	52.68%
Income	-188.41M	P/S	40.89	EPS this Y	32.78%	Inst Trans	3.21%	Short Ratio	6.96	Perf Half Y	91.52%
Sales	156.29M	P/B	-	EPS next Y	31.09%	ROA	-48.52%	Short Interest	4.97M	Perf YTD	71.88%
Book/sh	-0.19	P/C	21.96	EPS next 5Y	-	ROE	-1334.54%	52W High	106.52 -9.67%	Perf Year	96.01%
Cash/sh	4.38	P/FCF	-	EPS past 3/5Y	-45.66% -2.34%	ROIC	-77.44%	52W Low	45.90 109.61%	Perf 3Y	361.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	245.54% -	Gross Margin	88.81%	Volatility	3.70% 3.18%	Perf 5Y	222.02%
Dividend TTM	-	EV/Sales	40.69	EPS Y/Y TTM	30.87%	Oper. Margin	-113.53%	ATR (14)	3.33	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.64	Sales Y/Y TTM	53.55%	Profit Margin	-120.55%	RSI (14)	47.02	Recom	1.13
Dividend Gr. 3/5Y	- -	Current Ratio	2.79	EPS Q/Q	-36.96%	SMA20	-4.49%	Beta	2.14	Target Price	112.50
Payout	-	Debt/Eq	-	Sales Q/Q	66.80%	SMA50	3.85%	Rel Volume	0.75	Prev Close	97.92
Employees	283	LT Debt/Eq	-	Earnings	Aug 05 BMO	SMA200	43.71%	Avg Volume	713.98K	Price	96.22
IPO	Oct 05, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.92% 11.15%	Trades		Volume	532,003	Change	-1.74%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Initiated	Goldman	Buy	$97
Jul-07-25	Initiated	Leerink Partners	Outperform	$88
Apr-07-25	Upgrade	BofA Securities	Neutral → Buy	$63
Mar-05-25	Resumed	Stifel	Buy	$78
Jan-02-25	Initiated	Jefferies	Buy	$80
Dec-20-24	Initiated	Oppenheimer	Outperform	$76
Oct-21-24	Initiated	Guggenheim	Buy	$70
Sep-18-24	Initiated	H.C. Wainwright	Buy	$64
Sep-17-24	Initiated	JMP Securities	Mkt Outperform	$64
May-08-24	Downgrade	BofA Securities	Buy → Neutral	$49 → $42
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$29 → $55
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy	$22 → $27
Jan-18-23	Resumed	Canaccord Genuity	Buy	$52
Aug-08-22	Upgrade	Goldman	Neutral → Buy	$28
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral	$8 → $20
Jun-17-22	Reiterated	Needham	Buy	$40 → $25
Mar-02-22	Resumed	Stifel	Buy	$23
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy	$15
Dec-08-21	Initiated	Wells Fargo	Overweight	$30
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$50 → $15

Show Previous Ratings

Sep-01-25 01:04AM	Citizens JMP Keeps Market Outperform Rating on Rhythm Pharmaceuticals (RYTM) (Insider Monkey)
Aug-28-25 11:50PM	FDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM) (Insider Monkey)
Aug-27-25 04:01PM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 04:01PM	Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity (GlobeNewswire)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Aug-01-25 06:46AM	Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM) (Insider Monkey)
Jul-30-25 10:00AM	Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-29-25 10:00AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline (Zacks)
Jul-22-25 04:01PM	Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 (GlobeNewswire)
Jul-21-25 09:45AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Jul-12-25 06:00PM	Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 (GlobeNewswire)
05:30AM	Investing.coms stocks of the week (Investing.com)
Jul-10-25 11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
07:38AM	Rhythms stock climbs on encouraging Phase II obesity drug data (Clinical Trials Arena)
06:21AM	Loading…
06:21AM	Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jul-09-25 04:16PM	Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +36.63%
11:33AM	Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity (Investor's Business Daily)
08:00AM	Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity (GlobeNewswire)
Jul-08-25 04:01PM	Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity (GlobeNewswire)
Jun-25-25 08:00AM	Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025 (GlobeNewswire)
Jun-06-25 04:00PM	This IBD 50 Biotech's Got 'Rhythm' And Flashes 3 Telltale Clues (Investor's Business Daily)
Jun-05-25 08:06AM	This IBD 50 Biotech's Got 'Rhythm' - And Flashes 3 Telltale Clues (Investor's Business Daily)
May-29-25 12:50PM	Funds Go All In On Weight-Loss Leader; Stock Nears Highs (Investor's Business Daily)
May-14-25 08:00AM	Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program (GlobeNewswire)
May-08-25 03:10AM	Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... (GuruFocus.com) -6.05%
May-07-25 03:22PM	Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment (Seeking Alpha)
03:21PM	Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
08:00AM	Loading…
May-06-25 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-01-25 10:01AM	Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 10:01AM	Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-23-25 08:00AM	Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 (GlobeNewswire)
Apr-08-25 03:42PM	Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily) +5.04%
01:38PM	Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (Seeking Alpha)
12:10PM	5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008 (Zacks)
11:21AM	RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study (Zacks)
07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks)
Apr-07-25 04:09PM	This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5% (GuruFocus.com) +17.06%
12:30PM	Rhythm seeks market expansion for Imcivree following Phase III victory (Clinical Trials Arena)
12:23PM	Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder (Benzinga)
07:51AM	Obesity drug data helps Rhythm defy market slide (BioPharma Dive)
07:00AM	Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity (GlobeNewswire)
Apr-06-25 12:00PM	Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Mar-20-25 04:55PM	Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
04:01PM	Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE (setmelanotide) in China with Termination of Agreement with RareStone Ltd. (GlobeNewswire)
Mar-19-25 04:23PM	Rhythm Pharmaceuticals gets Orphan Drug status for its hypothalamic obesity treatment in Japan (SeekingAlpha) +5.58%
04:01PM	Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan (GlobeNewswire)
Mar-18-25 07:00AM	Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration (GlobeNewswire)
Feb-27-25 02:07AM	Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:38AM	Q4 2024 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 08:25AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily)
Feb-13-25 08:00AM	Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025 (GlobeNewswire)
Feb-05-25 08:00AM	Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February (GlobeNewswire)
Jan-28-25 09:55AM	Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet (Zacks)
Jan-22-25 08:50AM	Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Jan-10-25 07:15AM	Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones (GlobeNewswire)
Jan-02-25 10:15AM	Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential (TipRanks) +7.31%
Dec-20-24 02:24PM	Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential (Benzinga)
02:15PM	Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years Old (GlobeNewswire)
Dec-06-24 06:48AM	Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities (TipRanks)
Dec-03-24 06:00AM	Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old (GlobeNewswire)
Nov-18-24 12:02PM	Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone (Investor's Business Daily)
07:00AM	Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide (GlobeNewswire)
Nov-13-24 06:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology (GlobeNewswire) -6.23%
04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Nov-07-24 02:29AM	Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-24 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +11.38%
Nov-05-24 05:10PM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +6.15%
04:01PM	Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-04-24 04:01PM	Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek 2024 (GlobeNewswire) +8.12%
Oct-29-24 10:01AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-24-24 06:00AM	Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome (GlobeNewswire)
Oct-23-24 08:00AM	Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024 (GlobeNewswire)
Oct-08-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Sep-21-24 02:23AM	Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish (Insider Monkey)
Sep-18-24 10:46AM	Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Sep-16-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +7.37%
Sep-10-24 01:55PM	Biotech Stock Near Buy Point Amid Impressive Sales Track Record (Investor's Business Daily)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
Aug-26-24 08:02AM	Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE (setmelanotide) in Patients as Young as 2 years old (GlobeNewswire) +8.41%
08:00AM	Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September (GlobeNewswire)
Aug-13-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Aug-06-24 08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 09:10AM	Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old (GlobeNewswire)
Jul-23-24 08:00AM	Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity (GlobeNewswire)
07:30AM	Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 (GlobeNewswire)
Jul-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.00% +7.34%
Jul-08-24 08:00AM	Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jun-28-24 08:00AM	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency (GlobeNewswire)
Jun-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.36%
Jun-03-24 04:02PM	Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 (GlobeNewswire) +6.08%
08:02AM	Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference (GlobeNewswire)
May-22-24 04:00AM	Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for IMCIVREE (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome (GlobeNewswire)
May-09-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shulman Joseph	Chief Technical Officer	Sep 02 '25	Option Exercise	30.25	16,781	507,574	25,290	Sep 04 04:30 PM
Shulman Joseph	Chief Technical Officer	Sep 02 '25	Sale	105.30	16,781	1,767,006	8,509	Sep 04 04:30 PM
JOSEPH SHULMAN	Officer	Sep 02 '25	Proposed Sale	103.15	16,781	1,730,960		Sep 02 04:41 PM
Shulman Joseph	Chief Technical Officer	Aug 21 '25	Option Exercise	27.35	4,188	114,542	12,697	Aug 25 08:59 PM
Shulman Joseph	Chief Technical Officer	Aug 21 '25	Sale	100.07	4,188	419,091	8,509	Aug 25 08:59 PM
JOSEPH SHULMAN	Officer	Aug 21 '25	Proposed Sale	98.70	4,188	413,356		Aug 21 04:45 PM
Smith Hunter C	Chief Financial Officer	Aug 12 '25	Option Exercise	6.88	24,611	169,324	141,526	Aug 14 06:48 PM
Smith Hunter C	Chief Financial Officer	Aug 13 '25	Option Exercise	6.88	3,477	23,922	120,392	Aug 14 06:48 PM
Smith Hunter C	Chief Financial Officer	Aug 12 '25	Sale	96.33	24,611	2,370,832	116,915	Aug 14 06:48 PM
Smith Hunter C	Chief Financial Officer	Aug 13 '25	Sale	96.00	3,477	333,792	116,915	Aug 14 06:48 PM
German Christopher Paul	Corporate Controller & CAO	Aug 12 '25	Option Exercise	28.39	1,500	42,585	1,922	Aug 14 06:47 PM
German Christopher Paul	Corporate Controller & CAO	Aug 12 '25	Sale	95.00	1,500	142,500	922	Aug 14 06:47 PM
Shulman Joseph	Chief Technical Officer	Aug 11 '25	Option Exercise	6.80	3,984	27,091	12,493	Aug 13 06:32 PM
Shulman Joseph	Chief Technical Officer	Aug 11 '25	Sale	90.08	3,984	358,891	8,509	Aug 13 06:32 PM
HUNTER SMITH	Officer	Aug 12 '25	Proposed Sale	94.31	28,088	2,648,979		Aug 12 04:28 PM
CHRISTOPHER PAUL GERMAN	Officer	Aug 12 '25	Proposed Sale	94.31	1,500	141,465		Aug 12 04:26 PM
JOSEPH SHULMAN	Officer	Aug 11 '25	Proposed Sale	91.98	3,984	366,448		Aug 11 04:22 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 29 '25	Sale	85.93	1,520	130,614	20,814	Jul 29 06:56 PM
Smith Hunter C	Chief Financial Officer	Jul 09 '25	Option Exercise	6.88	42,120	289,786	159,035	Jul 11 04:31 PM
Smith Hunter C	Chief Financial Officer	Jul 09 '25	Sale	80.48	42,120	3,389,756	116,915	Jul 11 04:31 PM
Shulman Joseph	Chief Technical Officer	Jul 09 '25	Option Exercise	6.80	7,969	54,189	16,478	Jul 11 04:30 PM
Shulman Joseph	Chief Technical Officer	Jul 09 '25	Sale	77.78	7,969	619,851	8,509	Jul 11 04:30 PM
German Christopher Paul	Corporate Controller & CAO	Jul 09 '25	Option Exercise	27.29	2,850	77,786	4,739	Jul 11 04:30 PM
German Christopher Paul	Corporate Controller & CAO	Jul 09 '25	Sale	80.75	3,817	308,217	922	Jul 11 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 09 '25	Option Exercise	13.43	15,572	209,153	34,781	Jul 11 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 09 '25	Sale	77.13	15,572	1,201,062	19,209	Jul 11 04:30 PM
CHRISTOPHER PAUL GERMAN	Officer	Jul 09 '25	Proposed Sale	65.14	3,817	248,639		Jul 09 04:17 PM
PAMELA CRAMER	Officer	Jul 09 '25	Proposed Sale	65.14	15,572	1,014,360		Jul 09 04:17 PM
HUNTER SMITH	Officer	Jul 09 '25	Proposed Sale	65.14	42,120	2,743,697		Jul 09 04:16 PM
JOSEPH J SHULMAN	Officer	Jul 09 '25	Proposed Sale	65.14	7,969	519,101		Jul 09 04:16 PM
Smith Hunter C	Chief Financial Officer	Jul 07 '25	Option Exercise	6.88	6,986	48,064	116,915	Jul 08 04:30 PM
Garfield Alastair	Chief Scientific Officer	Jul 02 '25	Sale	64.81	1,319	85,483	3,126	Jul 03 05:12 PM
German Christopher Paul	Corporate Controller & CAO	Jun 10 '25	Option Exercise	17.97	1,069	19,210	3,958	Jun 12 04:50 PM
German Christopher Paul	Corporate Controller & CAO	Jun 10 '25	Sale	67.19	2,069	139,016	1,889	Jun 12 04:50 PM
Cramer Pamela J.	Chief Human Resources Officer	Jun 06 '25	Option Exercise	6.80	7,031	47,811	26,240	Jun 10 04:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Jun 06 '25	Sale	68.05	7,031	478,435	19,209	Jun 10 04:45 PM
CHRISTOPHER PAUL GERMAN	Officer	Jun 10 '25	Proposed Sale	66.72	2,069	138,044		Jun 10 04:21 PM
PAMELA CRAMER	Officer	Jun 06 '25	Proposed Sale	66.18	7,031	465,312		Jun 06 04:25 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Option Exercise	4.59	65,431	300,328	68,431	Jun 05 04:16 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Sale	65.22	65,431	4,267,494	3,000	Jun 05 04:16 PM
Meeker David P	President and CEO	Jun 03 '25	Option Exercise	4.59	43,620	200,216	245,445	Jun 05 04:16 PM
Meeker David P	President and CEO	Jun 03 '25	Sale	65.05	43,620	2,837,333	201,825	Jun 05 04:16 PM
DAVID W MCGIRR	Director	Jun 03 '25	Proposed Sale	63.66	65,431	4,165,337		Jun 03 04:27 PM
DAVID MEEKER	Director	Jun 03 '25	Proposed Sale	63.66	43,621	2,776,913		Jun 03 04:27 PM
Smith Hunter C	Chief Financial Officer	May 30 '25	Option Exercise	6.88	23,400	160,992	133,329	Jun 03 04:15 PM
Smith Hunter C	Chief Financial Officer	May 30 '25	Sale	61.41	23,400	1,437,010	109,929	Jun 03 04:15 PM
HUNTER SMITH	Officer	May 30 '25	Proposed Sale	61.88	23,400	1,447,992		May 30 04:35 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Option Exercise	6.80	7,031	47,811	26,240	May 01 04:53 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Sale	65.09	7,031	457,663	19,209	May 01 04:53 PM
Mazabraud Yann	EVP, Head of International	Apr 29 '25	Sale	65.08	6,745	438,946	37,655	May 01 04:52 PM
YANN MAZZABRAUD	Officer	Apr 29 '25	Proposed Sale	64.41	6,745	434,445		Apr 29 04:21 PM
PAMELA CRAMER	Officer	Apr 29 '25	Proposed Sale	64.41	7,031	452,867		Apr 29 04:20 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Option Exercise	13.43	20,760	278,853	39,969	Apr 10 05:17 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Sale	60.14	20,760	1,248,490	19,209	Apr 10 05:17 PM
Mazabraud Yann	EVP, Head of International	Apr 08 '25	Sale	60.99	17,750	1,082,497	22,620	Apr 10 05:16 PM
PAMELA CRAMER	Officer	Apr 08 '25	Proposed Sale	54.96	20,760	1,140,970		Apr 08 04:18 PM
YANN MAZZABRAUD	Officer	Apr 08 '25	Proposed Sale	54.96	17,750	975,540		Apr 08 04:16 PM
German Christopher Paul	Corporate Controller & CAO	Mar 21 '25	Sale	54.23	344	18,655	2,889	Mar 24 05:47 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Option Exercise	22.28	75,000	1,671,000	115,370	Mar 18 09:16 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Sale	51.48	75,000	3,861,272	40,370	Mar 18 09:16 PM
YANN MAZZABRAUD	Officer	Mar 14 '25	Proposed Sale	50.24	75,000	3,768,000		Mar 14 04:21 PM
Smith Hunter C	Chief Financial Officer	Feb 19 '25	Sale	57.22	2,215	126,742	109,929	Feb 19 09:50 PM
Shulman Joseph	Chief Technical Officer	Feb 19 '25	Sale	57.22	1,228	70,266	8,509	Feb 19 09:49 PM
Meeker David P	President and CEO	Feb 19 '25	Sale	57.22	9,896	566,249	201,281	Feb 19 09:48 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 19 '25	Sale	57.22	2,035	116,443	5,858	Feb 19 09:46 PM
German Christopher Paul	Corporate Controller & CAO	Feb 19 '25	Sale	57.22	635	36,335	2,070	Feb 19 09:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 19 '25	Sale	57.22	982	56,190	19,209	Feb 19 09:43 PM
Smith Hunter C	Chief Financial Officer	Feb 12 '25	Sale	56.39	751	42,347	105,544	Feb 14 04:59 PM
Shulman Joseph	Chief Technical Officer	Feb 12 '25	Sale	56.40	469	26,452	5,612	Feb 14 04:57 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 12 '25	Sale	56.39	1,815	102,348	3,598	Feb 14 04:55 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 13 '25	Sale	58.00	1,205	69,890	2,393	Feb 14 04:55 PM
JENNIFER KAYDEN LEE	Officer	Feb 13 '25	Proposed Sale	57.64	1,205	69,456		Feb 13 04:31 PM
JENNIFER KAYDEN LEE	Officer	Feb 12 '25	Proposed Sale	57.58	1,205	69,384		Feb 12 04:42 PM
Shulman Joseph	Chief Technical Officer	Feb 11 '25	Sale	57.51	794	45,663	6	Feb 11 09:47 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 09 '25	Option Exercise	6.80	4,189	28,485	8,598	Feb 11 09:46 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 10 '25	Sale	58.91	4,189	246,783	4,409	Feb 11 09:46 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 11 '25	Sale	57.51	1,027	59,063	5,413	Feb 11 09:46 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 11 '25	Sale	57.51	701	40,315	16,891	Feb 11 09:45 PM
Smith Hunter C	Chief Financial Officer	Feb 11 '25	Sale	57.51	1,296	74,533	106,295	Feb 11 09:44 PM
JENNIFER KAYDEN LEE	Officer	Feb 10 '25	Proposed Sale	59.18	4,189	247,905		Feb 10 04:34 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 05 '25	Sale	60.55	3,066	185,640	972	Feb 07 05:05 PM
JENNIFER KAYDEN LEE	Officer	Feb 05 '25	Proposed Sale	59.95	3,066	183,807		Feb 05 04:20 PM
Smith Hunter C	Chief Financial Officer	Feb 04 '25	Sale	59.43	1,678	99,724	101,186	Feb 04 09:27 PM
Shulman Joseph	Chief Technical Officer	Feb 04 '25	Sale	59.43	1,281	76,130	2,657	Feb 04 09:26 PM
Meeker David P	President and CEO	Feb 04 '25	Sale	59.43	4,278	254,242	189,927	Feb 04 09:25 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 04 '25	Sale	59.43	1,447	85,995	4,038	Feb 04 09:23 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 04 '25	Sale	59.43	902	53,606	15,248	Feb 04 09:22 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 11 '24	Option Exercise	19.59	60,981	1,194,709	67,833	Nov 13 09:04 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 11 '24	Sale	66.33	66,861	4,434,882	972	Nov 13 09:04 PM
Shulman Joseph	Chief Technical Officer	Nov 11 '24	Option Exercise	12.63	13,281	167,760	13,281	Nov 13 09:02 PM
Shulman Joseph	Chief Technical Officer	Nov 11 '24	Sale	66.44	13,281	882,341	0	Nov 13 09:02 PM
JENNIFER KAYDEN LEE	Officer	Nov 11 '24	Proposed Sale	67.33	66,861	4,501,751		Nov 12 07:55 AM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '24	Option Exercise	19.02	4,688	89,166	18,188	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 06 '24	Option Exercise	19.02	4,687	89,147	18,187	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '24	Sale	65.00	4,688	304,720	13,500	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 06 '24	Sale	60.00	4,687	281,220	13,500	Nov 08 04:15 PM
PAMELA CRAMER	Officer	Nov 07 '24	Proposed Sale	62.65	4,688	293,703		Nov 07 04:36 PM
PAMELA CRAMER	Officer	Nov 06 '24	Proposed Sale	56.25	4,687	263,644		Nov 06 05:07 PM
GOOD JENNIFER L	Director	Sep 17 '24	Option Exercise	21.54	31,751	684,066	34,751	Sep 19 04:30 PM
GOOD JENNIFER L	Director	Sep 17 '24	Sale	52.40	31,751	1,663,803	3,000	Sep 19 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RYTM

Rhythm Pharmaceuticals Inc

Upgrade your FINVIZ experience